Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies

BackgroundHPV 18 is one of the most prevalent oncogenic types, only second to HPV 16, and included in the licensed vaccines on the market. In this study, we describe the production and characterization of a panel of monoclonal antibodies (mAb) to HPV18.MethodsThe immunocompetence of 1B1 and 4C2 mAbs for HPV L1 protein was evaluated by SDS-PAGE analysis, neutralization assays, affinity identification, and ELISA. The 1B1 and 4C2 genes were sequenced and analyzed. Finally, the detection kit with the two mAbs was assessed for linearity, repeatability and specificity.ResultsBoth mAbs specifically recognized HPV18 L1 and virus-like particles (VLPs). These mAbs are conformation-neutralizing antibodies that have high affinity and type specificity. Based on these characteristics of these mAbs, we developed an ELISA kit for specifically detecting HPV 18 antigen. We showed that this kit displayed good linearity, repeatability and sensitivity for detecting HPV18 L1 pentamer and HPV18 VLP.ConclusionsWe characterized two monoclonal neutralizing antibodies for HPV L1 protein, and developed an ELISA kit for specifically detecting HPV 18 antigen. This newly developed kit can be used to monitor the potency of HPV vaccines throughout the entire production process as well as preliminary analysis of HPV18 infections.

• Publication year

  2018

• Venue

  Diagnostic Pathology

• Publication date

  2018-08-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13000-018-0727-7PMID 30115088PMCID 6097307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site.

  2017cited by this paper
• Human Papillomavirus Infection and Vaccination.

  2016cited by this paper
• Identification of rearranged sequences of HPV16 DNA in precancerous and cervical cancer cases.

  2016cited by this paper
• Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody

  2015cited by this paper
• Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France

  2015cited by this paper
• Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine

  2015cited by this paper
• Maturation of the Human Papillomavirus 16 Capsid

  2014cited by this paper
• Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein

  2014cited by this paper
• Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58

  2014cited by this paper
• The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon

  2014cited by this paper
• Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles.

  2012cited by this paper
• Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58

  2010cited by this paper
• Diseases caused by human papillomaviruses (HPV)

  2009cited by this paper
• Crystal Structures of Four Types of Human Papillomavirus L1 Capsid Proteins

  2007cited by this paper
• Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18

  2005cited by this paper
• Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

  2004cited by this paper
• Epidemiologic classification of human papillomavirus types associated with cervical cancer.

  2003cited by this paper
• Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

  2003cited by this paper
• Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

  2001cited by this paper
• Immunological analyses of human papillomavirus capsids.

  2001cited by this paper
• Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions

  1991cited by this paper
• Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus.

  1990cited by this paper
• Monoclonal antibodies to the major capsid protein of human papillomavirus type 1.

  1984cited by this paper

• Development of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein for COVID-19 antigen detection

  2025cites this paper
• Development and application of HPV31-specific monoclonal antibodies

  2023cites this paper
• Screening and detection of multivalent human papillomavirus antibodies using a high-throughput liquid chip fluoroimmunoassay system.

  2023cites this paper
• The Structural Profile of HPV 18 in Terms of Chromosomal and Nuclear Degenerative Changes and the Ratio of Nucleus/Cytoplasm on Liquid based Cervical Cells

  2023cites this paper
• Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer

  2021cites this paper
• Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

  2021cites this paper
• Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies

  2020cites this paper
• Nanobody against the E7 oncoprotein of human papillomavirus 16

  2019cites this paper
• Product review: avelumab, an anti-PD-L1 antibody

  2018cites this paper
• Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus

  2018cites this paper